<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01830010</url>
  </required_header>
  <id_info>
    <org_study_id>CKRP203A2105</org_study_id>
    <nct_id>NCT01830010</nct_id>
  </id_info>
  <brief_title>A Two-part Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of KRP203 in Patients Undergoing Stem Cell Transplant for Hematological Malignancies</brief_title>
  <official_title>A Two-part, Single- and Two Arm Randomized, Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy (in Part 2 Only) of KRP203 in Patients Undergoing Stem Cell Transplant for Hematological Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Two part study to evaluate the safety, tolerability, pharmacokinetics, and efficacy (in Part
      2 only) of KRP203 in patients undergoing allogeneic hemopoietic stem cell transplant for
      hematological malignancies
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">June 28, 2013</start_date>
  <completion_date type="Anticipated">August 24, 2018</completion_date>
  <primary_completion_date type="Anticipated">August 24, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with Adverse Events as a Measure of safety</measure>
    <time_frame>111 days</time_frame>
    <description>Safety and tolerability of KRP203 in patients undergoing allogeneic hematopoetic stem cell transplant for hematological malignancies</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Plasma Pharmacokinetics of KRP203: Area under the Plasma Concentration-time Curve (AUC)</measure>
    <time_frame>111 days</time_frame>
    <description>The main PK parameters will be determined in whole blood using non-compartmental methods. Pk parameters being measured are: AUCtau AUC during a dosing interval (tau) of 24 hours [h.ng/mL] , AUCtauR Molar ratios between KRP203-P and KRP203 based on Cmax or AUCtau</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Pharmacokinetics (PK) of KRP203: Observed Maximum Plasma Concentration Following Drug Administration (Cmax)</measure>
    <time_frame>111 days</time_frame>
    <description>Cmax Maximum (peak) blood drug concentration after drug administration [ng/mL]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Pharmacokinetics (PK) of KRP203: Time to reach the maximum concentration after drug administration</measure>
    <time_frame>111 days</time_frame>
    <description>Tmax Time to reach maximum (peak) concentration [ng/mL]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GVHD-free, relapse free survival</measure>
    <time_frame>1 years post-transplant</time_frame>
    <description>occurence of GVHD, disease relaps and death will be assessed</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GVHD-free, relapse free survival</measure>
    <time_frame>2 years post transplant</time_frame>
    <description>occurence of GVHD, disease relaps and death will be assessed</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">23</enrollment>
  <condition>Hematological Malignancies</condition>
  <arm_group>
    <arm_group_label>Study Part 1: KRP203</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All patients to receive KRP203 for 111days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Study Part 2: lower KRP203 dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>in this treatment arm patients will receive the lower KRP203 dose for 111 days on top of the standard treatment with cyclosporine A and methotrexte for GVHD prophylaxis</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Study Part 2: higher KRP203 dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>in this treatment arm patients will recieve the higher KRP203 dose for 111 days on top of standard treatment with tacrolimus and methotrexate for GVHD prophylaxis</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Study Part 1: KRP203</intervention_name>
    <description>All subjects will receive KRP203 for 111 days</description>
    <arm_group_label>Study Part 1: KRP203</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Study Part 2: KRP203 lower dose</intervention_name>
    <arm_group_label>Study Part 2: lower KRP203 dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Study Part 2: KRP203 higher dose</intervention_name>
    <arm_group_label>Study Part 2: higher KRP203 dose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

          -  Patients aged 18 to 65 years, inclusive

          -  Patients must have a hematological malignancy that as per standard medical practice
             requires myeloablative conditioning (including short term myeloablative reduced
             intensity conditioning) followed by allogeneic hematopoetic stem cell transplant

               -  Karnofsky Performance status ≥60%.

               -  Suitable stem cell source available according to the graft selection algorithm
                  using T-cell replete peripheral stem cells as a graft source

        Exclusion Criteria:

          -  Resting heart rate below 55

          -  Significant cardiac disease (such as arrhytmia, heart failure) or any significant
             condition which in the investigators opinion would make the patient ineligible

               -  Previous allogeneic HSCT

               -  Any drug required that is not compatible with KRP203 (e.g. beta-blockers or
                  anti-thymocyte globulin)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Paris</city>
        <zip>75010</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Regensburg</city>
        <state>Bavaria</state>
        <zip>93053</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Freiburg</city>
        <zip>79106</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Jena</city>
        <zip>07740</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Koeln</city>
        <zip>50937</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Basel</city>
        <zip>4031</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Zürich</city>
        <zip>8091</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>Germany</country>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 9, 2013</study_first_submitted>
  <study_first_submitted_qc>April 9, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 11, 2013</study_first_posted>
  <last_update_submitted>March 22, 2018</last_update_submitted>
  <last_update_submitted_qc>March 22, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 26, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.
This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

